Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy

BACKGROUND: Addition of oxaliplatin to capecitabine remains controversial for locally advanced rectal cancer (LARC). And cumulative oxaliplatin dose (COD) varied among clinical trials showing different therapeutic effects of this regimen. The objective of this study was to explore how COD affected t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Chang, Hui, Tao, Ya-lan, Jiang, Wu, Chen, Chen, Liu, Shi-liang, Ye, Wei-jun, Gao, Yuan-hong
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268650/
https://ncbi.nlm.nih.gov/pubmed/32487091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06988-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires